Related experiments have shown that single-dose bispecific targeting of FOLR1 and death receptor 5 (DR5) is an effective strategy for treating ovarian cancer, suggesting FOLR1 may be a potential biomarker for ovarian cancer (Shivange et al., 2018). The gene discussed is FOLR1; the disease is ovarian carcinoma.